Fed. Circ. Won't Let Jazz Keep System Patent In Orange Book

By Dani Kass · February 24, 2023, 7:43 PM EST

Jazz Pharmaceuticals must remove a patent from the Orange Book listing for its blockbuster narcolepsy drug Xyrem, as it covers neither the drug itself nor a method of using it, the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

November 28, 2022

Recent Articles By Dani

July 10, 2024
Drug Pricing, Overreach Dominate IP Disclaimer Feedback
May 28, 2024
Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor
April 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor
February 20, 2024
Fed. Circ. Backs Microsoft's PTAB Win Over 3D Patents
February 08, 2024
HHS Won't Invoke IP Rights To Lessen Xtandi Prices
January 30, 2024
CDC Patent Apps Lead Gilead To Victory In HIV Research Feud
January 11, 2024
NJ Judge Not Convinced Epidiolex Seller Lied To USPTO
December 13, 2023
The Biggest Patent Rulings Of 2023
November 17, 2023
FDA's Lack Of Power May Limit FTC's Patent Challenge
November 02, 2023
Nonprofit Calls For CMS-Amgen Price Talks To Reflect Abuse